Arena Pharmaceuticals, Inc.
NASDAQ: ARNA
$99.99
+$0.00 (+0.0%)
Closing Price on March 15, 2022
ARNA Articles
ThinkstockArena Pharmaceuticals Inc. (NASDAQ: ARNA) is posing yet one more threat to ambitious biotechs and drug-makers who are targeting the obesity market. Its stock is getting slapped by almost...
Published:
ThinkstockBack in December, we took an in-depth look at what has become a crowded race in the obesity drug market. As we pointed out then, the race has become a battle of not only who has the drug...
Published:
Last Updated:
ThinkstockSome of the biggest business stories of the past year drew the most Internet search traffic to the newsmakers, which is really no big surprise. Whether just for curiosity or for help in...
Published:
Last Updated:
ThinkstockAccording to the Centers for Disease Control (CDC), more than one-third (35.7%) of all adults in the United States are obese. Obesity-related medical conditions include heart attack,...
Published:
ThinkstockWe have tracked the key short interest changes in the following biotech and emerging pharma companies: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Amgen Inc. (NASDAQ: AMGN), Arena...
Published:
We have tracked the key short interest changes in the following biotech and emerging pharma companies: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Amgen Inc. (NASDAQ: AMGN), Arena Pharmaceuticals...
Published:
Last Updated:
The short interest in biotech stocks is mixed, judging by the short interest changes between the September 14 and September 28 settlement dates. There were notable swings in shares sold short from...
Published:
Last Updated:
With a couple of exceptions, the short interest in biotech stocks is on the rise again, judging by the short interest changes from September 14 settlement date versus the August 31 settlement date....
Published:
The short interest in biotech stocks is generally falling, judging by the short interest changes from August 31 settlement date versus the August 15 settlement date. We have tracked the key short...
Published:
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen from Wall St. research calls this Thursday. Activision Blizzard Inc. (NASDAQ: ATVI) raised to Overweight at Piper...
Published:
Last Updated:
The short interest in biotech stocks is generally rising, judging by the short interest changes from August 15 settlement date versus the July 31 settlement date. We have tracked the key short...
Published:
The history of weight loss drugs is sketchy at best. But VIVUS Inc. (NASDAQ: VVUS) is making up on all of its recent losses, after shares slid from almost $30 to just under $26.46 at yesterday’s...
Published:
Last Updated:
What usually happens when you get two mergers announced in drugs and biotech in the same day? Investors begin to wonder which other peers and competitors might be on the M&A block. Monday’s...
Published:
Last Updated:
More biotech mergers are on the way! That is the verdict of Wall St. There may be patent protection risks associated with future regulation under health care, but deals in the biotech and emerging...
Published:
Last Updated:
The freshly announced multibillion biotech buyout of Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) for more than $5 billion in equity value may be a bit misleading if you consider that it is...
Published:
Last Updated: